(1H-imidazol-5-yl)(phenyl)methanol | 78892-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1H-imidazol-5-yl)(phenyl)methanol
• 英文别名: rac-5-(hydroxy-phenyl-methyl)-1H-imidazole；(1H-Imidazol-4-yl)(phenyl)methanol；1H-imidazol-5-yl(phenyl)methanol
• CAS: 78892-29-2
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: LLMALNLCFQLWHG-UHFFFAOYSA-N

物化性质

• 沸点：
  433.4±30.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  Phenyl-(1-tritylimidazol-4-yl)methanone 在 甲醇 、 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 (1H-imidazol-5-yl)(phenyl)methanol
  参考文献：
  名称：

  Co(III) 催化烯胺酮与恶二唑酮偶联合成咪唑

  摘要：

  本文报道了与骨架物种形成导向合成的传统智慧相反的附件物种形成导向合成，强调附件的类型、位置和构型变化的最大化。根据这种合成方式建立了 Co(III) 催化方案，用于将烯胺酮和恶二唑酮与咪唑偶联，从而实现附属物的完全位置变化。这意味着反应和结构开发范围的扩大，可以为高效的有机合成提供肥沃的土壤。

  DOI：

  10.1021/acs.orglett.4c02736

文献信息

• [EN] IMIDAZOLE DERIVATIVES AS IDO INHIBITORS<br/>[FR] DÉRIVÉS IMIDAZOLE COMME INHIBITEURS DE L'IDO
  申请人：NEWLINK GENETICS

  公开号：WO2011056652A1

  公开（公告）日：2011-05-12

  Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是通用结构式（VII）、（VIII）所示的IDO抑制剂及其药物组合物，用于调节色胺酸2,3-二氧化酶的活性；治疗色胺酸2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于色胺酸-2,3-二氧化酶酶活性抑制的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制。
• Simultaneous Deprotection and Purification Based on Ionic Resin Capture: Application to Amide Formations and Grignard and Mitsunobu Reactions
  作者：Peter Meier、Sascha Müller

  DOI：10.1055/s-2007-983758

  日期：——

  Tr-protected amines were caught directly out of reaction mixtures by simultaneous cleavage of the protecting group. By releasing the products with ammonia the corresponding free amines were obtained in high yields and purities. The broadly applicable method of simultaneous deprotection and purification based on ionic resin capture was applied for Grignard and Mitsunobu reactions as well as amide formations

  通过同时裂解保护基团，将含有 Boc-或 Tr-保护胺的产物直接从反应混合物中捕获。通过用氨释放产物，以高产率和纯度获得相应的游离胺。基于离子树脂捕获的广泛适用的同时脱保护和纯化方法被应用于格氏反应和光信反应以及酰胺形成，并显示出多平行合成的高潜力。
• Methods for treating CNS disorders with 4-imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197622A1

  公开（公告）日：2007-08-23

  The present invention relates to methods for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, Ar, R 1 , R 1′ , R 2 , and n are as defined in the specification and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神疾病，如精神分裂症、神经疾病，如帕金森病、神经退行性疾病，如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收的障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律的障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的R、Ar、R1、R1'、R2和n如规范中所定义，并且包括它们的药物活性盐、外消旋混合物、对映异构体和互变异构体。本发明还涉及化合物I的新型化合物、含有它们的组合物以及它们的制备方法。
• Imidazole Derivatives as IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20120277217A1

  公开（公告）日：2012-11-01

  Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是通式（VII），（VIII）所示的IDO抑制剂及其制药组合物，用于调节吲哚胺2,3-二氧化酶的活性；治疗由吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于抑制吲哚胺2,3-二氧化酶酶活性的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染病相关的免疫抑制。
• Imidazole derivatives as IDO inhibitors
  申请人：Mautino Mario R.

  公开号：US08722720B2

  公开（公告）日：2014-05-13

  Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是通式（VII）、（VIII）所示的IDO抑制剂及其药物组成物，可用于调节吲哚胺2,3-二氧化酶的活性；治疗吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于抑制吲哚胺-2,3-二氧化酶酶活性的医学情况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制。